Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

KALYANA JANGA

NPI
1154518199
CMS profile
1301256
Location
BROOKLYN, NY

General Payments · PY2018–2024

$5,941.62

  • Reported across 94 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$2,704.44

12 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Relypsa, Inc. $2,415.24 5
Medtronic, Inc. $143.51 1
Acerta Pharma LLC $54.84 2
AKEBIA THERAPEUTICS INC $24.61 1
Aurinia Pharma U.S., Inc. $23.89 1
Novo Nordisk AS $21.29 1
Fresenius USA Marketing, Inc. $21.06 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $944.74 8
PY2019 $297.09 10
PY2020 $544.94 20
PY2021 $237.79 12
PY2022 $367.02 13
PY2023 $845.60 19
PY2024 $2,704.44 12

Payment records · PY2024 (12)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
AKEBIA THERAPEUTICS INC $24.61 11/14/2024 Education Undisputed 01/23/2026 1145834361 CMS
AstraZeneca Pharmaceuticals LP $27.22 02/09/2024 Food and Beverage Undisputed 01/23/2026 1110510860 CMS
AstraZeneca Pharmaceuticals LP $27.62 02/29/2024 Food and Beverage Undisputed 01/23/2026 1110513728 CMS
Aurinia Pharma U.S., Inc. $23.89 07/23/2024 Food and Beverage Undisputed 01/23/2026 1150683606 CMS
Fresenius USA Marketing, Inc. $21.06 02/20/2024 Food and Beverage Undisputed 01/23/2026 1154212004 CMS
Medtronic, Inc. $143.51 02/23/2024 Food and Beverage Undisputed 01/23/2026 1116861422 CMS
Novo Nordisk Inc $21.29 02/21/2024 Food and Beverage Undisputed 01/23/2026 1108580347 CMS
Vifor Pharma, Inc. $1,137.50 05/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1124033155 CMS
Vifor Pharma, Inc. $85.18 05/13/2024 Travel and Lodging Undisputed 01/23/2026 1124033160 CMS
Vifor Pharma, Inc. $11.31 05/13/2024 Food and Beverage Undisputed 01/23/2026 1124033164 CMS
Vifor Pharma, Inc. $1,056.25 11/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1124062671 CMS
Vifor Pharma, Inc. $125.00 11/21/2024 Food and Beverage Undisputed 01/23/2026 1124062675 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.